A bioinformatics approach for the phenotype prediction of nonsynonymous single nucleotide polymorphisms in human cytochromes P450E

Drug Metabolism and Disposition

Volumn 37, Issue 5, 2009, Pages 977-991

  Wang, Lin Lin ^a,b   Li, Yong ^a   Zhou, Shu Feng ^b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b RMIT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450;

ALGORITHM; AMINO ACID SUBSTITUTION; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; GENETIC ALGORITHM; GENETIC DATABASE; HUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; QUALITY CONTROL; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; SWISS-PROT;

ALGORITHMS; AMINO ACID SUBSTITUTION; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, GENETIC; EXONS; HUMANS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; TERMINOLOGY AS TOPIC;

EID: 66449133554     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.026047     Document Type: Article

References (63)

1. Biason-Lauber A, Kempken B, Werder E, Forest MG, Einaudi S, Ranke MB, Matsuo N, Brunelli V, Schonle EJ, and Zachmann M (2000) 17alpha-Hydroxylase/17, 20-lyase deficiency as a model to study enzymatic activity regulation: role of phosphorylation. J Clin Endocrinol Metab 85:1226-1231.
2. Brown PJ, Bedard LL, Reid KR, Petsikas D, and Massey TE (2007) Analysis of CYP2A contributions to metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone in human peripheral lung microsomes. Drug Metab Dispos 35:2086-2094.
3. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, et al. (1999) Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 22:231-238.
4. Chasman D and Adams RM (2001) Predicting the functional consequences of non-synonymous single nucleotide polymorphisms: structure-based assessment of amino acid variation. J Mol Biol 307:683-706.
5. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, and Gueritte F (2002) Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 30:438-445.
6. D'Agostino J, Zhang X, Wu H, Ling G, Wang S, Zhang QY, Liu F, and Ding X (2008) Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers. Drug Metab Dispos 36:2316-2323.
7. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, and Goldstein JA (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597-607.
8. Daigo S, Takahashi Y, Fujieda M, Ariyoshi N, Yamazaki H, Koizumi W, Tanabe S, Saigenji K, Nagayama S, Ikeda K, et al. (2002) A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 12:299-306.
9. Desta Z, Zhao X, Shin JG, and Flockhart DA (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913-958.
10. Domanski TL and Halpert JR (2001) Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. Curr Drug Metab 2:117-137.
11. Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedel E, Hustert E, Zanger UM, Brockmoller J, Klenk HP, Meyer UA, et al. (2001) Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447-458.
12. Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, et al. (1998) A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 284:356-361.
13. Ferrer-Costa C, Orozco M, and de la Cruz X (2002) Characterization of disease-associated single amino acid polymorphisms in terms of sequence and structure properties. J Mol Biol 315:771-786.
14. Gupta MK, Geller DH, and Auchus RJ (2001) Pitfalls in characterizing P450c17 mutations associated with isolated 17,20-lyase deficiency. J Clin Endocrinol Metab 86:4416-4423.
15. Hamosh A, Scott AF, Amberger JS, Bocchini CA, and McKusick VA (2005) Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 33:D514-D517.
16. Helmberg A, Tusie-Luna MT, Tabarelli M, Kofler R, and White PC (1992) R339H and P453S: CYP21 mutations associated with nonclassic steroid 21-hydroxylase deficiency that are not apparent gene conversions. Mol Endocrinol 6:1318-1322.
17. Henikoff S and Henikoff JG (1992) Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci USA 89:10915-10919.
18. Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, Ballinger DG, Frazer KA, and Cox DR (2005) Whole-genome patterns of common DNA variation in three human populations. Science 307:1072-1079.
19. Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, and Goldstein JA (1999) A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 290:635-640.
20. Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Daly AK, and Goldstein JA (1998a) An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 8:129-135.
21. Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, Ghanayem BI, and Blaisdell J (1998b) Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 286:1490-1495.
22. Ingelman-Sundberg M, Sim SC, Gomez A, and Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526.
23. Joehrer K, Geley S, Strasser-Wozak EM, Azziz R, Wollmann HA, Schmitt K, Kofler R, and White PC (1997) CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Hum Mol Genet 6:1829-1834.
24. King BP, Khan TI, Aithal GP, Kamali F, and Daly AK (2004) Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 14:813-822.
25. King LM, Ma J, Srettabunjong S, Graves J, Bradbury JA, Li L, Spiecker M, Liao JK, Mohrenweiser H, and Zeldin DC (2002) Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 61:840-852.
26. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Murdter TE, Roots I, and Brockmoller J (2003) Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619-626.
27. Kitagawa K, Kunugita N, Kitagawa M, and Kawamoto T (2001) CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J Biol Chem 276:17830-17835.
28. Lajic S, Clauin S, Robins T, Vexiau P, Blanche H, Bellanne-Chantelot C, and Wedell A (2002) Novel mutations in CYP21 detected in individuals with hyperandrogenism. J Clin Endocrinol Metab 87:2824-2829.
29. Lehnerer M, Schulze J, Achterhold K, Lewis DF, and Hlavica P (2000) Identification of key residues in rabbit liver microsomal cytochrome P450 2B4: importance in interactions with NADPH-cytochrome P450 reductase. J Biochem 127:163-169.
30. Liu J, Lewohl JM, Harris RA, Dodd PR, and Mayfield RD (2007) Altered gene expression profiles in the frontal cortex of cirrhotic alcoholics. Alcohol Clin Exp Res 31:1460-1466.
31. Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L, Eckloff BW, Schaid D, Wieben ED, Adjei AA, et al. (2005) Human aromatase: gene resequencing and functional genomics. Cancer Res 65:11071-11082.
32. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, et al. (2006) Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics 16:497-514.
33. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, Meyer UA, and Broly F (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193-202.
34. Miners JO and Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
35. Monno S, Ogawa H, Date T, Fujioka M, Miller WL, and Kobayashi M (1993) Mutation of histidine 373 to leucine in cytochrome P450c17 causes 17 alpha-hydroxylase deficiency. JBiol Chem 268:25811-25817.
36. Nadeau JH (2002) Single nucleotide polymorphisms: tackling complexity. Nature 420:517-518. Nebert DW and Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360:1155-1162.
37. Ng PC and Henikoff S (2002) Accounting for human polymorphisms predicted to affect protein function. Genome Res 12:436 -446.
38. Ng PC and Henikoff S (2006) Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 7:61-80.
39. Ng PC and Henikoff S (2003) SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31:3812-3814.
40. Oscarson M, McLellan RA, Gullsten H, Aguundez JA, Benitez J, Rautio A, Raunio H, Pelkonen O, and Ingelman-Sundberg M (1999) Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett 460:321-327.
41. Ramensky V, Bork P, and Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30:3894-3900.
42. Ravichandran KG, Boddupalli SS, Hasermann CA, Peterson JA, and Deisenhofer J (1993) Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. Science 261:731-736.
43. Rudberg I, Mohebi B, Hermann M, Refsum H, and Molden E (2008) Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 83:322-327.
44. Schlicht KE, Michno N, Smith BD, Scott EE, and Murphy SE (2007) Functional characterization of CYP2A13 polymorphisms. Xenobiotica 37:1439 -1449.
45. Stenson PD, Ball E, Howells K, Phillips A, Mort M, and Cooper DN (2008) Human Gene Mutation Database: towards a comprehensive central mutation database. J Med Genet 45:124-126.
46. Stitziel NO, Tseng YY, Pervouchine D, Goddeau D, Kasif S, and Liang J (2003) Structural location of disease-associated single-nucleotide polymorphisms. J Mol Biol 327:1021-1030.
47. Sunyaev S, Ramensky V, Koch I, Lathe W 3rd, Kondrashov AS, and Bork P (2001) Prediction of deleterious human alleles. Hum Mol Genet 10:591-597.
48. Tajima T, Fujieda K, Nakayama K, and Fujii-Kuriyama Y (1993) Molecular analysis of patient and carrier genes with congenital steroid 21-hydroxylase deficiency by using polymerase chain reaction and single strand conformation polymorphism. J Clin Invest 92:2182-2190.
49. Terp BN, Cooper DN, Christensen IT, J0rgensen FS, Bross P, Gregersen N, and Krawczak M (2002) Assessing the relative importance of the biophysical properties of amino acid substitutions associated with human genetic disease. Hum Mutat 20:98 -109.
50. Tomalik-Scharte D, Lazar A, Fuhr U, and Kirchheiner J (2008) The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 8:4-15.
51. Wang Z and Moult J (2001) SNPs, protein structure, and disease. Hum Mutat 17:263-270.
52. Williams PA, Cosme J, Sridhar V, Johnson EF, and McRee DE (2000) Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 5:121-131.
53. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, and Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305:683-686.
54. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, and Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424:464-468.
55. Xi T, Jones IM, and Mohrenweiser HW (2004) Many amino acid substitution variants identified in DNA repair genes during human population screenings are predicted to impact protein function. Genomics 83:970-979.
56. Xu CF, Lewis K, Cantone KL, Khan P, Donnelly C, White N, Crocker N, Boyd PR, Zaykin DV, and Purvis IJ (2002) Effectiveness of computational methods in haplotype prediction. Hum Genet 110:148 -156.
57. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 279:38091- 38094.
58. Zhang X, Su T, Zhang QY, Gu J, Caggana M, Li H, and Ding X (2002) Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J Pharmacol Exp Ther 302:416-423.
59. Zhernakova A, van Diemen CC, and Wijmenga C (2009) Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 10:43-55.
60. Zhou S, Paxton JW, Tingle MD, and Kestell P (2000) Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metab Dispos 28:1449 -1456.
61. Zhou SF (2008) Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310-322.
62. Zhou SF, Chan E, Zhou ZW, Xue CC, Lai X, and Duan W (2009) Insights into the structure, function, and regulation of human cytochrome P450 1A2. Curr Drug Metab, in press.
63. Zhou SF, Di YM, Chan E, Du YM, Chow VD, Xue CC, Lai X, Wang JC, Li CG, Tian M, et al. (2008) Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 9:738 -784.